Edgewise Therapeutics (Edgewise Therapeutics) Net Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Edgewise Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Edgewise Therapeutics's Net Income for the three months ended in Dec. 2023 was $-30.14 Mil. Edgewise Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Edgewise Therapeutics's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Edgewise Therapeutics's Net Margin % or its related term are showing as below:

EWTX's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -160.92
* Ranked among companies with meaningful Net Margin % only.

Edgewise Therapeutics Net Margin % Historical Data

The historical data trend for Edgewise Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edgewise Therapeutics Net Margin % Chart

Edgewise Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Edgewise Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Edgewise Therapeutics's Net Margin %

For the Biotechnology subindustry, Edgewise Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edgewise Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Edgewise Therapeutics's Net Margin % falls into.

Edgewise Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Edgewise Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-100.163	/	0
	=	%

Edgewise Therapeutics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-30.143	/	0
	=	%

Edgewise Therapeutics (NAS:EWTX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Edgewise Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Edgewise Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Edgewise Therapeutics (Edgewise Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edgewise Therapeutics Inc (NAS:EWTX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3415 Colorado Avenue, Boulder, CO, USA, 80303

Website

https://www.edgewisetx.com

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Executives

John R Moore	officer: General Counsel	3200 WALNUT ST, BOULDER CO 80301
Alan J Russell	director, officer: Chief Scientific Officer	3415 COLORADO AVE, BOULDER CO 80303
Jonathan C Fox	director	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
R Michael Carruthers	officer: Chief Financial Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Behrad Derakhshan	officer: Chief Business Officer	3415 COLORADO AVE., BOULDER CO 80303
Kevin Koch	director, officer: President and CEO	3200 WALNUT ST, BOULDER CO 80301
Joanne M. Donovan	officer: CMO	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139
Marc Semigran	officer: Chief Development Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Orbimed Capital Gp Vi Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan D Root	director	2735 SAND HILL ROAD, MENLO PARK CA 94025
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017